---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332767"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2026-08-04T20:05:17+00:00"
generated_at: "2026-08-04T20:06:19.231125+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q2 revenue up 21% to $189.9M; net income falls to $0.41 EPS; raises FY guidance low end

## Summary
- Total revenue $189.9M (+21% YoY); product revenue $111.2M (+16%), service revenue $78.8M (+29%).
- Net income $14.7M ($0.41 diluted EPS) vs $0.92 prior year; adjusted net income $16.2M ($0.44 adjusted EPS).
- Raised low end of FY2026 revenue guidance (excl. PAD Aviation) to $737M-$757M.
- Completed strategic investment in PAD Aviation on July 1, 2026 to establish European organ transplant air logistics network.

## SEC filing metadata
- accession: 0001193125-26-332767
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2026-08-04T20:05:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/0001193125-26-332767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/tmdx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332767
- JSON: https://secwatch.observer/filing/0001193125-26-332767.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.